- Aytu BioScience press release ( NASDAQ: AYTU ): FQ4 GAAP EPS of -$0.49 misses by $0.12 .
- Revenue of $27.45M (+16.9% Y/Y) beats by $1.95M .
- Cash and cash equivalents at the end of the fiscal year ended June 30, 2022 were $19.4 million.
- Subsequent to the end of the year, the Company raised $10.0 million in gross proceeds in a registered public offering.
- Prescription segment Adjusted EBITDA was a positive $1.1 million, while Consumer Health was $(2.1) million resulting in a combined Adjusted EBITDA of $(1.0) million for the Company's commercial business. This compares to Adjusted EBITDA of $(5.5) million for the Prescription segment and $(2.7) million for the Consumer Health segment in Q4 2021, resulting in a combined Adjusted EBITDA of $(8.2) million for the Company's commercial business.
- Shares +5.26% .
For further details see:
Aytu BioScience GAAP EPS of -$0.49 misses by $0.12, revenue of $27.45M beats by $1.95M